www.hivandhepatitis.com

Back HCV Treatment

Anadys to Halt Development of Investigational Hepatitis C Drug ANA975

Details
Category: Experimental HCV Drugs
Published on Friday, 03 August 2007 14:03
Written by Anadys
  • Print

Anadys Pharmaceuticals announced last week that it will discontinue development of its investigational anti-HCV drug candidate, ANA975, a toll-like receptor 7 agonist.Anadys was developing the agent in collaboration with Novartis. The decision comes in the wake of disappointing data from toxicology studies in animals. Toll-like receptor agents can cause excessive immune stimulation, leading to a range of side effects.

Read more:

Subcategories

Copyright © 2023 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design